Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patients

Abstract Anti-EGFR antibodies are effective in therapies for late-stage colorectal cancer (CRC); however, many tumours are unresponsive or develop resistance. We performed genomic analysis of intrinsic and acquired resistance to anti-EGFR therapy in prospectively collected tumour samples from 25 CRC...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Steven M. Bray, Jeeyun Lee, Seung Tae Kim, Joon Young Hur, Philip J. Ebert, John N. Calley, Isabella H. Wulur, Thejaswini Gopalappa, Swee Seong Wong, Hui-Rong Qian, Jason C. Ting, Jiangang Liu, Melinda D. Willard, Ruslan D. Novosiadly, Young Suk Park, Joon Oh Park, Ho Yeong Lim, Won Ki Kang, Amit Aggarwal, Hee Cheol Kim, Christoph Reinhard
Format:	article
Langue:	EN
Publié:	Nature Portfolio 2019
Sujets:	Medicine R Science Q
Accès en ligne:	https://doaj.org/article/f456fa8deb9947ea89d5b6e8de43eb83
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Soyez le premier à ajouter un commentaire!

Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patients

Documents similaires